^
Association details:
| Biomarker: | RET C634R |
|---|---|
| Cancer: | Thyroid Gland Medullary Carcinoma |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer
Excerpt:
Of the 16 patients with sporadic MTC, 12 had tumor DNA samples of sufficient quantity for RET genotype testing. Ten of 12 patients tested were positive for a RET mutation (nine with M918T and one with C634R). All patients with the RET M918T mutation had had PD within 12 months of study entry or were newly diagnosed just before study entry. Of the two patients with PR, one had hereditary MTC with the RET C634R mutation, and the other had sporadic MTC with the RET M918T mutation.
DOI:
10.1200/JCO.2009.25.0068
Trial ID:
Source:
Title:
Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer
Excerpt:
Of the two patients with PR, one had hereditary MTC with the RET C634R mutation, and the other had sporadic MTC with the RET M918T mutation.
DOI:
10.1200/JCO.2009.25.0068
